<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094663</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0168</org_study_id>
    <nct_id>NCT03094663</nct_id>
  </id_info>
  <brief_title>Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)</brief_title>
  <acronym>IPACK</acronym>
  <official_title>Analgesia After Total Knee Arthroplasty: Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI). A Double-Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of two pain control methods - the combination of Adductor Canal Block&#xD;
      (ACB)/Periarticular Injection (PAI)/Infiltration of the interspace between the popliteal&#xD;
      artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI)&#xD;
      - in patients undergoing total knee arthroplasty. Primary outcome is NRS pain scores with&#xD;
      ambulation on postoperative day one (24 hours post-block administration).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS Pain Scores</measure>
    <time_frame>24 hours post block administration</time_frame>
    <description>NRS Pain scores with ambulation 24 hours post block administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>24 hours on Post-Operative Day 1, 48 hours on Post-Operative Day 2, and 72 hours on Post-Operative Day 3</time_frame>
    <description>Opioid consumption at different intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS at Rest and with movement</measure>
    <time_frame>24 hours on Post-Operative Day 1, 48 hours on Post-Operative Day 2, and 72 hours on Post-Operative Day 3</time_frame>
    <description>NRS at rest and with movement at different intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Therapy milestones</measure>
    <time_frame>It will be assessed on 24 hours on Post-Operative Day 1, 48 hours on Post-Operative Day 2, and 72 hours on Post-Operative Day 3</time_frame>
    <description>Milestones include time to ambulate and time to reach discharge criteria set by Physical Therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction with Pain Control using the likert scale</measure>
    <time_frame>Post-Operative Day 2</time_frame>
    <description>Satisfaction with Pain control at different intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PainOUT</measure>
    <time_frame>Post-Operative Day 1 and Post-Operative Day 2</time_frame>
    <description>PainOUT scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>It will be assessed on 24 hours on Post-Operative Day 1, 48 hours on Post-Operative Day 2, and 72 hours on Post-Operative Day 3</time_frame>
    <description>Length of Stay (LOS) calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Related Symptom Distress Scale (ORSDS)</measure>
    <time_frame>Post-Operative Day 1 and Post-Operative Day 2</time_frame>
    <description>ORSDS scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr)</measure>
    <time_frame>baseline and 6 weeks post op</time_frame>
    <description>KOOS Jr scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Knee Arthropathy</condition>
  <arm_group>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)&#xD;
Injection prior to cementation&#xD;
bupivacaine 0.5% with epinephrine 30cc;&#xD;
methylprednisolone, 40 mg/ml, 1 ml&#xD;
cefazolin, 500 mg in 10 ml&#xD;
normal saline, 22cc&#xD;
Superficial injection prior to closure.&#xD;
20cc 0.25% bupivacaine&#xD;
2 mg IV dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)&#xD;
Injection prior to cementation&#xD;
bupivacaine 0.25% with epinephrine 30cc;&#xD;
methylprednisolone, 40 mg/ml, 1 ml&#xD;
cefazolin, 500 mg in 10 ml&#xD;
normal saline, 22cc&#xD;
Superficial injection prior to closure.&#xD;
a. 20cc 0.25% bupivacaine&#xD;
Adductor canal block technique (supine position, post IV sedation)&#xD;
a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone&#xD;
IPACK technique (supine position) a. 25 cc 0.25% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>0.5% with epinephrine 30cc</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>40 mg/ml, 1 ml</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>500 mg in 10 ml</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>8 MHz. Chiba needle</intervention_name>
    <description>22G/ 4 inches</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 cc of bupivacaine 0.25% with 2 mg of preservative free Dexamethasone</intervention_name>
    <description>15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone</description>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 cc 0.25% bupivacaine</intervention_name>
    <description>25 cc 0.25% bupivacaine</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20cc 0.25% bupivacaine</intervention_name>
    <description>20cc 0.25% bupivacaine</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections, Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg IV dexamethasone.</intervention_name>
    <description>2 mg IV dexamethasone.</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine 0.5% with epinephrine 30cc</intervention_name>
    <description>bupivacaine 0.5% with epinephrine 30cc</description>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with osteoarthritis scheduled for a primary either partial or total knee&#xD;
             arthroplasty with a participating surgeon&#xD;
&#xD;
          -  Age 18 to 80 years&#xD;
&#xD;
          -  Planned use of regional anesthesia&#xD;
&#xD;
          -  Ability to follow study protocol&#xD;
&#xD;
          -  English speaking (secondary outcomes include questionnaires validated in English only)&#xD;
&#xD;
          -  Patients of participating surgeons&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic or renal insufficiency&#xD;
&#xD;
          -  Younger than 18 years old and older than 80&#xD;
&#xD;
          -  Patients undergoing general anesthesia&#xD;
&#xD;
          -  Allergy or intolerance to one of the study medications&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  ASA of IV&#xD;
&#xD;
          -  Chronic gabapentin/pregabalin use (regular use for longer than 3 months)&#xD;
&#xD;
          -  Chronic opioid use (taking opioids for longer than 3 months, or daily oral morphine&#xD;
             equivalent of &gt;5mg/day for one month)&#xD;
&#xD;
          -  Patients with severe valgus deformity and flexion contracture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher T Garnett, BA</last_name>
    <phone>212-774-7022</phone>
    <email>GarnettC@hss.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George Birch, BA</last_name>
    <phone>212-774-7377</phone>
    <email>BirchG@hss.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital For Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher T Garnett, BA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IPACK</keyword>
  <keyword>PAI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

